232 related articles for article (PubMed ID: 34807269)
21. Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.
Li S; Deng K; Qiu J; Wang P; Yin D; Xie Y; Yu Y
Technol Cancer Res Treat; 2024; 23():15330338241256859. PubMed ID: 38780516
[No Abstract] [Full Text] [Related]
22. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI.
Elsayes KM; Kielar AZ; Elmohr MM; Chernyak V; Masch WR; Furlan A; Marks RM; Cruite I; Fowler KJ; Tang A; Bashir MR; Hecht EM; Kamaya A; Jambhekar K; Kamath A; Arora S; Bijan B; Ash R; Kassam Z; Chaudhry H; McGahan JP; Yacoub JH; McInnes M; Fung AW; Shanbhogue K; Lee J; Deshmukh S; Horvat N; Mitchell DG; Do RKG; Surabhi VR; Szklaruk J; Sirlin CB
Abdom Radiol (NY); 2018 Oct; 43(10):2625-2642. PubMed ID: 30155697
[TBL] [Abstract][Full Text] [Related]
23. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
[TBL] [Abstract][Full Text] [Related]
24. MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.
Shin J; Lee S; Hwang JA; Lee JE; Chung YE; Choi JY; Park MS
Eur Radiol; 2022 May; 32(5):3319-3326. PubMed ID: 35031839
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
26. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
27. Can absolute arterial phase hyperenhancement improve sensitivity of detection of hepatocellular carcinoma in indeterminate nodules on CT?
Zafar S; Elbanna KY; Todd AWM; Guimaraes L; O'Brien C; Goel A; Kim TK; Khalili K
Eur Radiol; 2024 Apr; 34(4):2256-2268. PubMed ID: 37775590
[TBL] [Abstract][Full Text] [Related]
28. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
[TBL] [Abstract][Full Text] [Related]
30. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
[TBL] [Abstract][Full Text] [Related]
31. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Tang A; Alhasan AS; Allen BC; Reiner CS; Clarke C; Cerny M; Wang J; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kang Z; Kierans AS; Kim SY; Kwon H; Ronot M; Podgórska J; Rosiak G; Song JS; Bashir MR
Radiology; 2023 Dec; 309(3):e231656. PubMed ID: 38112549
[TBL] [Abstract][Full Text] [Related]
32. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
33. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
[TBL] [Abstract][Full Text] [Related]
34. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
[TBL] [Abstract][Full Text] [Related]
35. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
[TBL] [Abstract][Full Text] [Related]
36. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?
Kim SS; Hwang JA; Shin HC; Choi SY; Kang TW; Jou SS; Lee WH; Park S; Heo NH
Eur Radiol; 2019 Jan; 29(1):186-194. PubMed ID: 30073499
[TBL] [Abstract][Full Text] [Related]
37. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
[TBL] [Abstract][Full Text] [Related]
38. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
[TBL] [Abstract][Full Text] [Related]
39. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
[TBL] [Abstract][Full Text] [Related]
40. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
